2024
706 - Real-world patient experience of upadacitinib-treated adults with atopic dermatitis: results from the SCALE-UP study
Silverberg J, Calimlim B, Fuxench Z, Altman K, Bensimon A, Liu J, Bunick C. 706 - Real-world patient experience of upadacitinib-treated adults with atopic dermatitis: results from the SCALE-UP study. British Journal Of Dermatology 2024, 191: ljae266.080. DOI: 10.1093/bjd/ljae266.080.Peer-Reviewed Original ResearchPatient support programAtopic dermatitisItch improvementSkin clearanceOral Janus kinase inhibitorPatient experiencePhase 3 clinical trialsTreating moderate-to-severe ADEffect of upadacitinibMultiple phase 3 clinical trialsModerate-to-severe ADJanus kinase inhibitorsClinical trial resultsPatient-reported experiencesDecreased quality of lifeEvaluate patient experiencePatient-reported outcomesTopical corticosteroidsPatient ageCross-sectional analysisQuality of lifeUpadacitinib dosesKinase inhibitorsUpadacitinibTreatment duration
2023
42262 Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)
Silverberg J, Deleuran M, Gold L, Bunick C, Hijnen D, Calimlim B, Teixeira H, Platt A, Grada A, Hu X, Gooderham M. 42262 Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up). Journal Of The American Academy Of Dermatology 2023, 89: ab90. DOI: 10.1016/j.jaad.2023.07.365.Peer-Reviewed Original Research